HanmiCap® - Proprietary 5' Cap analogs for in vitro transcription
| HanmiC ap® 07 | Order Quantity | USD/umol | Total Price (USD) | Grade |
|---|---|---|---|---|
|
1 μmol |
Inquiry (Click) |
Inquiry (Click) |
R&D ------------- Clinical Trials |
| 5 μmol | ||||
| 10 μmol | ||||
| 50 μmol | ||||
| 100 μmol |
· HanmiCap®07 is the 1st generation of HanmiCap® AG, which showed comparable performance to the commercial cap analog.
· HanmiCap® IP was approved by the Korean Intellectual Property Office (Patent No. 10-2692464), and is going through international approval through PCT.
· Initial test sample provided for free (10 μmol)
· No additional running royalties
· GMP Manufacturing available
Product Performance
| Group | Construct | Capping Efficiency (%) |
|---|---|---|
| CCAG | Luciferase mRNA - CommercialCap AG (3’OMe) | 97.6% |
| HC07 | Luciferase mRNA - HanmiCap® 07 | 97.1% |
· Perform measurement of mRNA capping efficiency by LC/MS
· HanmiCap® 07 showed comparable capping efficiency against the Commercial Cap AG (3'OMe).
HEK-293s Luciferase Readings
· HanmiCap® 07 showed comparable in vitro Luciferase expression against the Commercial Cap AG (3'OMe) after HEK-293s cell transfection.